ILXQuant Mental Health and Psychedelic Medicine Basket Index

Fixed-basket index of 10 companies at the frontier of the mental health treatment revolution -- pure-play psychedelic developers (COMPASS Pathways, atai Life Sciences, MindMed), approved CNS innovators (Axsome, Acadia, Intra-Cellular), neuroactive steroids (Sage), and established neuroscience platforms (Jazz, Alkermes, Biogen). The FDA Breakthrough Therapy designations for psilocybin-assisted therapy represent the largest paradigm shift in psychiatry since the introduction of SSRIs. Rebalances quarterly to equal weight.

Index identifier
ILXMND
Category
Basket
Universe
Fixed basket -- 10 mental health and psychedelic medicine companies (equal weight)
Currency
USD
Inception
2021-09-07
Rebalancing
Quarterly (first Monday of March, June, September, December)
Index fee
0.60% p.a.
Reference benchmark
Health Care SPDR (XLV)

Performance and risk

All figures below are measured over a trailing window of up to 1,260 trading days (approximately five years), not since index inception.

Performance and risk — 2021-09-07 to 2026-08-13 00:00:00
Annualised return+9.28%
Sharpe ratio0.28
Calmar ratio0.24
Volatility33.19%
Maximum drawdown-38.20%
Return, 1 month
Return, 3 months
Return, 1 year
Return, year to date+11.49%

Full performance history, drawdown analysis, rolling risk metrics and portfolio breakdowns for this index are available in the ILX Quant platform.